Eli Lilly and Company $LLY Shares Purchased by Corient Private Wealth LLC

Corient Private Wealth LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 620,126 shares of the company’s stock after buying an additional 20,698 shares during the quarter. Eli Lilly and Company comprises approximately 0.7% of Corient Private Wealth LLC’s portfolio, making the stock its 22nd biggest holding. Corient Private Wealth LLC owned approximately 0.07% of Eli Lilly and Company worth $483,407,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Laurel Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the period. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $8,827,714,000. Finally, Jennison Associates LLC raised its position in shares of Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after buying an additional 226,620 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LLY. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Morgan Stanley boosted their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Bank of America cut their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday. The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research note on Monday. Finally, UBS Group increased their price target on Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,128.55.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,062.67 on Tuesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm has a market capitalization of $1.00 trillion, a P/E ratio of 51.99, a P/E/G ratio of 1.14 and a beta of 0.37. The company’s fifty day moving average price is $943.82 and its two-hundred day moving average price is $822.76.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the firm earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.